Theranostics in Hematooncology

In the early 2000s, major clinical trials provided evidence of a favorable outcome from antibody-mediated radioimmunotherapy for hematologic neoplasms, which then led to Food and Drug Administration approval. For instance, the theranostic armamentarium for the referring hematooncologist now includes...

Descripción completa

Detalles Bibliográficos
Autores principales: Buck, Andreas K., Serfling, Sebastian E., Kraus, Sabrina, Samnick, Samuel, Dreher, Niklas, Higuchi, Takahiro, Rasche, Leo, Einsele, Hermann, Werner, Rudolf A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2023
Materias:
Continuing Education
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315699/
https://www.ncbi.nlm.nih.gov/pubmed/37290799
http://dx.doi.org/10.2967/jnumed.122.265199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315699/
https://www.ncbi.nlm.nih.gov/pubmed/37290799
http://dx.doi.org/10.2967/jnumed.122.265199

Ejemplares similares